NCT04134390 - Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

November 22, 2023

Study Completion Date

November 22, 2023

Conditions

Old Age; DebilityRenal Carcinoma Metastatic

Interventions

DRUG

Cabozantinib

Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation

Trial Locations (10)

46009

Fundación Instituto Valenciano de Oncologia, Valencia

Unknown

Hospital de Ciudad Real, Ciudad Real

ICO L'Hospitalet, L'Hospitalet de Llobregat

Hospital Insular de Gran Canarias, Las Palmas de Gran Canaria

Hospital Lucus Augusti, Lugo

Hospital Infanta Sofia, Madrid

Hospital Universitario de Donostia, San Sebastián

Hospital Doctor Peset, Valencia

Hospital Universitario La Fe, Valencia

Hospital Clinico de Valladolid, Valladolid

All Listed Sponsors

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER